Cytomegalovirus infection – Diagnostics – Overview of Information and Clinical Research

Diagnosing cytomegalovirus infection involves different approaches depending on who is being tested and why. For most healthy people, testing is not routinely needed since the virus rarely causes noticeable problems. However, for pregnant women, newborn babies, and people with weakened immune systems, accurate and timely diagnosis can be crucial for managing health risks and preventing serious complications.

Introduction: Who Should Undergo Diagnostics

Most people who come into contact with cytomegalovirus will never know they have been infected because their bodies fight off the virus without creating any symptoms. For this reason, testing for CMV (short for cytomegalovirus) is not recommended for the general healthy population. The body’s immune system usually keeps the virus under control, and the infection remains inactive for life after the initial exposure.^[1]

However, diagnostic testing becomes important in specific situations where CMV could pose serious health risks. Pregnant women should consider testing if they develop symptoms that might indicate a new CMV infection, such as fever, extreme tiredness, sore throat, or swollen glands. This is particularly important if they have been exposed to someone known to have active CMV, especially if they work with or care for young children under age five, who are common carriers of the virus.^[1]^[7]

Testing is also advisable for pregnant women when an ultrasound examination suggests that the developing baby might have a CMV infection. In these cases, doctors need to determine whether the mother has recently acquired the virus or if it is an old infection that has reactivated. The timing of infection during pregnancy affects the risk to the baby, with new infections posing higher risks.^[8]

People with weakened immune systems should undergo CMV diagnostics as well. This includes individuals living with HIV or AIDS, those who have received organ transplants, stem cell transplants, or bone marrow transplants, and patients undergoing chemotherapy. In these cases, even an old CMV infection can reactivate and cause severe illness affecting multiple organs.^[2]^[3]

Newborn babies need testing if they show signs of congenital CMV infection at birth or shortly after. Symptoms that warrant testing include low birth weight, yellowing of the skin and eyes (called jaundice), an unusually small head size, seizures, or a skin rash with purple spots. Even babies who appear healthy at birth should be tested if they fail their routine newborn hearing screening, as CMV is the leading non-genetic cause of hearing loss in children.^[4]^[5]

⚠️ Important

For newborns, timing is critical. CMV testing using saliva or urine must be completed within the first two to three weeks of life to confirm whether the baby was born with the infection (congenital CMV). After this window, a positive test cannot distinguish between an infection present at birth and one acquired after delivery, making early diagnosis essential for proper treatment decisions.^[4]

Diagnostic Methods Used to Identify CMV Infection

Healthcare providers use several laboratory tests to detect CMV infection, and the choice of test depends on who is being tested and what information is needed. Blood tests are commonly used for adults and older children who show symptoms that might be caused by CMV. These tests look for either the virus itself or for proteins called antibodies that the immune system produces in response to the infection.^[8]

When testing for antibodies in blood, doctors can determine not only whether someone has been infected with CMV but also when the infection likely occurred. The body produces different types of antibodies at different stages of infection. Fresh infections trigger the production of antibodies called IgM, while older infections are characterized by the presence of IgG antibodies. These antibodies can remain in the blood for months or even years after infection, providing a window into a person’s CMV history.^[8]

For pregnant women, antibody testing serves an important purpose. If a pregnant woman has symptoms suggesting CMV or has been exposed to the virus, her healthcare provider may order blood tests to see if she has antibodies from a past infection or if she appears to be experiencing a new infection. Finding antibodies that suggest a recent infection is concerning during pregnancy because it means there is a higher chance the virus could pass to the developing baby through the placenta.^[8]

If antibody tests suggest a pregnant woman has a new CMV infection, additional testing may be recommended to check whether the baby has been infected. A procedure called amniocentesis can be performed, where a healthcare provider uses a needle to collect a sample of the fluid surrounding the baby in the womb (amniotic fluid). This fluid is then tested in a laboratory to look for the presence of CMV. However, amniocentesis is generally only recommended when imaging tests like ultrasound show certain signs that might indicate CMV infection in the developing baby.^[8]

For newborn babies, blood is not the most reliable fluid for testing. Instead, doctors prefer to test saliva or urine because these fluids are more likely to contain the virus if a baby was born with congenital CMV. A simple swab of the inside of the baby’s cheek can collect saliva, or urine can be collected in a bag or cup. These samples are sent to a laboratory where technicians look for CMV genetic material using a technique called polymerase chain reaction or PCR, which can detect even tiny amounts of the virus.^[4]^[12]

People with weakened immune systems may need different types of testing depending on their symptoms and which organs might be affected by CMV. Blood tests can measure the amount of virus circulating in the bloodstream, which helps doctors understand how active the infection is. This measurement is particularly important for transplant recipients, as the level of virus in the blood (called viral load) can predict whether serious organ damage might occur.^[3]

When CMV affects specific organs, doctors may need to examine tissue samples directly. For example, if someone with a weakened immune system has symptoms suggesting CMV is affecting their lungs, stomach, or intestines, a procedure called endoscopy or bronchoscopy might be performed. During these procedures, a thin tube with a camera is inserted into the body to view the affected area, and small tissue samples (biopsies) can be collected and examined under a microscope to look for signs of CMV damage.^[6]

For people experiencing vision problems that might be caused by CMV infection of the eyes (CMV retinitis), an eye doctor can examine the back of the eye using a special instrument. CMV retinitis creates a characteristic appearance that experienced doctors can recognize, though sometimes eye fluid may be tested to confirm the diagnosis.^[6]

Distinguishing CMV from other infections can be challenging because many viruses cause similar symptoms. In healthy people, CMV infection can look very much like mononucleosis caused by Epstein-Barr virus, with fever, fatigue, sore throat, and swollen lymph nodes. Blood tests that look for both viruses help doctors determine which one is responsible. Similarly, in people with weakened immune systems, other viruses or infections can cause symptoms that overlap with those of CMV, so comprehensive testing is often needed.^[1]^[3]

Diagnostics for Clinical Trial Qualification

Clinical trials testing new treatments for CMV infection or methods to prevent congenital CMV use specific diagnostic criteria to determine which patients can participate. These criteria ensure that study participants truly have the condition being studied and that their health status is well-documented before any experimental treatment begins.^[13]

For trials involving newborns with congenital CMV, enrollment typically requires laboratory confirmation of the infection within the first three weeks of life. Researchers need this early confirmation to distinguish babies who were born with CMV from those who might have acquired it during or after birth through contact with infected breast milk or other sources. Trials often require both urine and saliva tests showing positive results for CMV genetic material using PCR technology.^[13]

Many trials for congenital CMV treatment also require documentation of the baby’s symptoms and the extent of organ involvement. This might include hearing tests, eye examinations, brain imaging using ultrasound or MRI, blood tests to check liver and kidney function, and blood cell counts. These baseline measurements help researchers understand each baby’s condition before treatment starts and allow them to track whether the treatment makes a difference.^[13]^[8]

Clinical trials evaluating treatments for CMV in people with weakened immune systems have different requirements. For transplant recipients, trials may require regular monitoring of CMV viral load in blood samples, even before symptoms appear. Some trials test a preventive approach (called prophylaxis) where antiviral medication is given to prevent CMV from becoming active, while others use a preemptive strategy where treatment starts only when laboratory tests detect the virus in the blood, before the person develops symptoms.^[9]

In these trials, participants must undergo frequent blood testing to measure how much virus is present and whether it is increasing or decreasing in response to treatment. The frequency of testing varies but may be as often as once or twice per week during high-risk periods after transplantation. Additional tests monitor for medication side effects, including blood counts to check for neutropenia (low white blood cell counts) and tests of kidney and liver function.^[9]^[13]

⚠️ Important

Before enrolling in a CMV clinical trial, participants and their families should understand the testing requirements and commitment involved. Trials may require numerous clinic visits, frequent blood draws, and careful documentation of any symptoms. However, participation contributes to medical knowledge and may provide access to promising new treatments not yet available to the general public.

Trials testing vaccines to prevent CMV infection in pregnant women establish baseline testing to confirm that women do not already have CMV antibodies at enrollment. These trials typically recruit women who are seronegative, meaning their blood tests show no evidence of past CMV infection, because the goal is to see if the vaccine can prevent first-time infections. Participants undergo regular blood testing throughout pregnancy and after delivery, and their babies are tested for CMV at birth and during follow-up visits.^[20]

For all types of CMV clinical trials, standardized laboratory methods are used to ensure that results can be compared across different study sites. Laboratories performing the testing must meet quality standards and often use the same testing procedures and equipment. This standardization is essential for determining whether a new treatment or prevention method truly works better than existing options.^[3]

Prognosis and Survival Rate

Prognosis

The outlook for people with CMV infection varies dramatically depending on their immune system status and whether the infection is present at birth. For healthy children and adults, the prognosis is excellent. Most people who get CMV never develop symptoms or experience only mild, flu-like illness that resolves on its own within three weeks without treatment. Once infected, the virus remains in the body for life in an inactive state, but it rarely causes future problems for people with normal immune function.^[1]^[7]

The prognosis becomes more concerning for babies born with congenital CMV. Most babies with congenital CMV appear healthy at birth and remain well throughout their lives. However, about one in five babies born with CMV will develop complications over time. The most common long-term problem is hearing loss, which can be present at birth or develop gradually during childhood. This hearing loss may affect one or both ears and can range from mild to severe. Some children also experience developmental delays, vision problems, or learning disabilities.^[4]^[5]

Babies who show symptoms of CMV infection at birth (called symptomatic congenital CMV) face a higher risk of serious complications. These symptoms might include a small head size, seizures, liver problems, or a rash. Over ninety percent of babies with symptoms at birth will have serious long-term complications, which may include hearing loss, visual impairment, intellectual disability, epilepsy, or in rare cases, death. Early antiviral treatment started within the first month of life may improve hearing and developmental outcomes for these babies, though it does not cure the infection.^[5]^[13]

For people with weakened immune systems, the prognosis depends on how severely their immunity is compromised and how quickly CMV infection is detected and treated. In transplant recipients and people with advanced HIV, CMV can cause life-threatening illness affecting the lungs, digestive system, brain, or eyes. Before effective antiviral medications became available, CMV retinitis frequently led to blindness in people with AIDS. With current treatments and immune system support, many people can control CMV reactivation, though the risk of serious complications remains higher than in healthy individuals.^[2]^[3]

Survival Rate

For healthy people infected with CMV, survival is not affected. The virus does not cause life-threatening illness in individuals with normal immune systems, and people live normal lifespans despite carrying the virus.^[1]

Among babies born with congenital CMV, the survival rate is generally high, but some severely affected infants do not survive. Approximately 400 children die each year in the United States from complications of congenital CMV infection. Death is most likely in babies born with severe symptoms affecting multiple organs, particularly those with significant brain damage or overwhelming infection at birth.^[4]

Before modern antiviral medications and preventive strategies became available, CMV was a major cause of death in transplant recipients. CMV reactivation was associated with high mortality rates, especially in the first year after organ or stem cell transplantation. Today, with regular monitoring, preventive medications, and early treatment of infection, survival rates have improved substantially. However, CMV infection and disease still contribute to increased mortality in transplant recipients and can lead to rejection of transplanted organs.^[3]^[9]

In people living with HIV, the survival outlook for CMV-related complications improved dramatically with the introduction of effective antiretroviral therapy that controls HIV and strengthens the immune system. Before these medications were available, CMV retinitis and other CMV-related conditions were common causes of death in people with AIDS. Now, with immune system restoration through HIV treatment and the availability of antiviral medications for CMV, survival rates are much better, though CMV remains a concern when HIV is not well controlled.^[6]

#1 Clinical Trials Search in Europe